Cytosorbents logo

CytosorbentsNASDAQ: CTSO

Profile

Sector:

Healthcare

Country:

United States

IPO:

08 August 2006

Next earnings report:

14 March 2025

Last dividends:

N/A

Next dividends:

N/A
$52.47 M
-77%vs. 3y high
35%vs. sector
-vs. 3y high
-vs. sector
-45%vs. 3y high
76%vs. sector
-75%vs. 3y high
32%vs. sector

Price

regular market | 95 min ago
$0.96+$0.01(+1.00%)

Dividend

No data over the past 3 years
$8.61 M$9.63 M
$8.61 M-$2.33 M

Analysts recommendations

Institutional Ownership

CTSO Latest News

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India
globenewswire.com11 November 2024 Sentiment: POSITIVE

PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio.

Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript
seekingalpha.com09 November 2024 Sentiment: NEUTRAL

Cytosorbents Corporation (NASDAQ:CTSO ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Adanna Alexander - IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Tom Kerr - Zacks Small-Cap Research Operator Thank you for standing by. My name is Catherine, and I will be your conference operator today.

CytoSorbents Reports Second Quarter 2024 Financial and Operational Results
globenewswire.com13 August 2024 Sentiment: POSITIVE

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended June 30, 2024.

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
globenewswire.com13 August 2024 Sentiment: POSITIVE

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J.

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results
globenewswire.com07 August 2024 Sentiment: POSITIVE

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2024 operating and financial results after the market close on Tuesday, August 13, 2024.

CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website
globenewswire.com30 July 2024 Sentiment: POSITIVE

PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of its newly redesigned and consolidated website at www.cytosorbents.com.

CytoSorbents Secures $20 Million Credit Facility
globenewswire.com02 July 2024 Sentiment: POSITIVE

PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that on June 28, 2024, the Company entered into a new $20 million credit facility with Avenue Capital Group, including its Avenue Venture Opportunities Fund, L.P.

CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript
Seeking Alpha14 March 2024 Sentiment: POSITIVE

CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript

Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript
Seeking Alpha09 November 2023 Sentiment: NEUTRAL

Cytosorbents Corporation (CTSO) Q3 2023 Earnings Call Transcript

Cytosorbents Corporation (CTSO) Q2 2023 Results Earnings Conference Call
Seeking Alpha01 August 2023 Sentiment: POSITIVE

Cytosorbents Corporation. (NASDAQ:CTSO ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Taylor Devlin - Revenue Accountant Phillip Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathleen Bloch - Interim Chief Financial Officer Efthymios Deliargyris - Chief Medical Officer Christopher Cramer - Senior Vice President of Business Development Irina Kulinets - Senior Vice President of Regulatory Conference Call Participants Joshua Jennings - TD Cowen Laura Suriel - Alliance Global Partners Sean Lee - H.C.

What type of business is Cytosorbents?

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. The company also develops CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, and removal of anti-A and anti-B blood group antibodies from whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it develops BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove drugs and chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

What sector is Cytosorbents in?

Cytosorbents is in the Healthcare sector

What industry is Cytosorbents in?

Cytosorbents is in the Medical Devices industry

What country is Cytosorbents from?

Cytosorbents is headquartered in United States

When did Cytosorbents go public?

Cytosorbents initial public offering (IPO) was on 08 August 2006

What is Cytosorbents website?

https://www.cytosorbents.com

Is Cytosorbents in the S&P 500?

No, Cytosorbents is not included in the S&P 500 index

Is Cytosorbents in the NASDAQ 100?

No, Cytosorbents is not included in the NASDAQ 100 index

Is Cytosorbents in the Dow Jones?

No, Cytosorbents is not included in the Dow Jones index

When was Cytosorbents the previous earnings report?

No data

When does Cytosorbents earnings report?

The next expected earnings date for Cytosorbents is 14 March 2025